Third Rock Ventures IV, L.P. - 03 Feb 2025 Form 4 Insider Report for Maze Therapeutics, Inc. (MAZE)

Footnote F1

Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series D-1 Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a one-for-0.1037 basis without payment of consideration. The Preferred Stock had no expiration date.

Footnote F2

The shares are held directly by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV, and TRV GP IV LLC, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Footnote F3

The shares are held directly by Third Rock Ventures V, L.P. ("TRV V"). The general partner of TRV V is Third Rock Ventures GP V, L.P. ("TRV GP V"). The general partner of TRV GP V is TRV GP V, LLC ("TRV GP V LLC"). Each of TRV GP V, and TRV GP V LLC, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Footnote F4

Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between the TRV IV related parties and the TRV V related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.